OKE vs ZYME · P/E 15, rev $21.70B vs rev $76.3M
ONEOK Inc (OKE) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
ONEOK Inc (OKE) is a oil & gas midstream company listed on NYSE.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported OKE revenue for 2024-12-31 was $21.70B. Net income was $3.11B. Revenue was up 22.7% from 2023-12-31 to 2024-12-31. OKE currently screens at market cap $53.92B and trailing P/E 15.3.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
OKE currently screens at market cap $53.92B and trailing P/E 15.3. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the OKE and ZYME stock pages for the full models.
Not investment advice.